Yonex Announced as Official Partner for the 2024 Australian Open; Marking 9 Consecutive Years and Stringing 57,000 Racquets

2 years ago

Naomi Osaka shares her unique stringing preference; one of the many athletes that will rely on Yonex this summer. MELBOURNE,…

NCS announces expanded collaboration with Microsoft to accelerate AI and Cloud Innovation

2 years ago

Collaboration includes creation of a dedicated growth engine in NCS, as well as new Intellectual Property (IP) and end-to-end solutions,…

WSPN Forges Strategic Alliance with Fireblocks to Advance Digital Payments Ecosystem

2 years ago

HONG KONG--(BUSINESS WIRE)--WSPN, a leading global digital payments company, proudly announces a strategic collaboration with Fireblocks, an enterprise platform to…

AOC’s Gifting Choices: Find Your Perfect Match

2 years ago

SINGAPORE - Media OutReach Newswire - 11 January 2024 - Embark on a thrilling journey with AOC, the distinguished display…

OPPO kicks off the imagine IF Photography Awards 2024, igniting a new wave in creativity through mobile photography

2 years ago

SHENZHEN, CHINA - Media OutReach Newswire - 11 January 2024 - Leading global technology company OPPO launched the 2024 edition…

Nexif Ratch Energy Appoints Cyril Dissescou As Chief Executive Officer

2 years ago

HONG KONG SAR - Media OutReach Newswire - 11 January 2024 - Nexif Ratch Energy Investments Pte. Ltd. ("Nexif Ratch…

Nexif Ratch Engergy Appoints Cyril Dissescou As Chief Executive Officer

2 years ago

HONG KONG SAR - Media OutReach Newswire - 11 January 2024 – Nexif Ratch Energy Investments Pte. Ltd. ("Nexif Ratch…

SIBUR attains the largest portfolio of climate projects among Russian companies

2 years ago

MOSCOW, RUSSIA - Media OutReach Newswire - 11 January 2024 - The Russian Registry of Carbon Units has welcomed three…

Zai Lab Announces The New England Journal of Medicine Publication Demonstrating Durable Clinical Activity of Repotrectinib in Patients with Advanced ROS1 Fusion-Positive NSCLC

2 years ago

Phase 1/2 TRIDENT-1 study data demonstrate repotrectinib’s clinically meaningful response rates and durable clinical activity in patients with ROS1-positive non-small…